NEW YORK, Sept. 4, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Kiromic BioPharma, Inc.’s securities KRBP: (i) pursuant to and/or traceable to the offering documents issued in connection with the Company’s initial public offering on or about July 2, 2021 (the “IPO”); and/or (ii) between June 25, 2021 and August 13, 2021, both dates inclusive (the “Class Period”), the important October 4, 2022 Deadline for Lead Plaintiff.

SO WHAT: If you have purchased Kiromic BioPharma securities, you may be entitled to compensation without payment of out-of-pocket expenses or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To participate in the Kiromic BioPharma fundraiser, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action. A class action lawsuit has already been filed. If you want to appear as lead plaintiff, you must call the court by October 4, 2022 at the latest. A lead plaintiff is a representative party acting on behalf of other group members in conducting the litigation.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Many of these law firms do not actually conduct securities class actions, but are merely intermediaries who refer clients or work with law firms who actually hear the cases. Be wise in choosing a lawyer. The Rosen law firm represents investors worldwide and focuses its practice on securities class actions and shareholder derivatives litigation. Rosen Law Firm has achieved the largest-ever settlement of a securities class action lawsuit against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for number of securities class action lawsuits…